PHARMARESEARCH BIO Co., Ltd.
Developed the botulinum toxin drug Lientox, holding both Korean marketing approval and export authorization.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2009 and listed on KONEX in 2015, PharmaResearch Bio is a pharmaceutical company specializing in botulinum toxin drugs. It completed a dedicated botulinum toxin plant in 2017 and obtained export authorization, and on February 1, 2024 received Korean MFDS marketing approval for its botulinum toxin drug Lientox. In a muscle paralysis efficacy test on rats, its product showed efficacy equivalent to Allergan's original Botox, and in the first quarter of 2019 it passed an MFDS GMP inspection confirming the suitability of its Biosafety Level 3 dedicated botulinum toxin production facility.
Products & technology
- LientoxBotulinum toxin drug
Regulatory approvals
data.go.kr3 Korean MFDS drug approvals · 2019–2024
- MFDS drugRe N Tox Injection 100Units(Clostridium botulinum toxin type A)2024-02-01Drug · Prescription · Approval202400243
- MFDS drugRientox Inj. 200Unit(for export)2020-11-24Drug · Prescription · Approval202008174
- MFDS drugRientox Inj. 100Unit(for export)2019-02-15Drug · Prescription · Approval201900955
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2019–2020 (Phase 3 1 · Phase 1 1)
- Phase 3BCD2002020-06-08
3 trial sites
- Phase 1BCD2002019-01-04
1 trial site
R&D and key agreements
Source: DART corporate disclosure리엔톡스 비임상시험 · 근육 마비(미용 및 치료목적) · 비임상 완료, 품목허가 취득 · Rat muscle paralysis efficacy test confirmed effect equivalent to original Botox
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIOAI-SearchBot2
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 25, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition